A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Overview of attention for article published in Clinical Cancer Research, November 2017

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 9,066 followers.

Top story from Clinical Cancer Research this week! https://t.co/Wz2nRTwOFG

A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant https://t.co/6hfAtbtV1H

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.